Compare Quest Diagnostics Inc (DGX) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs PayPal Holdings, Inc. — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while PayPal Holdings, Inc. trades at $56.51 (market cap $41.79B). The key difference: PayPal Holdings, Inc. is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | PYPL | |
|---|---|---|
Market Cap | $22.80B | $41.79B |
Sector | Health | Financials |
52-Week High | $216.02 | $78.22 |
52-Week Low | $166.42 | $39.08 |
Enterprise Value | $28.82B | $41.85B |
Dividend Yield | 1.67% | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
PayPal (PYPL) trades at $47.65, up 2.87% on the day, with a bullish technical signal from moving averages but overbought RSI readings near 78. The stock shows strong fundamentals with a P/E of 8.94, net income margin of 15%, and consistent revenue growth to $33.17B in 2025. Recent news includes a potential acquisition offer from Stripe and Advent at $60.50 per share, valuing the company over $53 billion, alongside expansion of BNPL services in the UK.
PYPL presents a compelling value opportunity with low valuation multiples and solid profitability, though execution risks and competitive pressures remain. The acquisition speculation adds upside potential, but investors face volatility from earnings misses and regulatory scrutiny. Wall Street sentiment is mixed with a $48.36 consensus target, slightly above the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
